Preclinical studies have demonstrated that the inhibition of Bcl-XL and/or MCL-1 exhibits significant anti-AML activity and enhances the sensitivity of venetoclax in AML treatment (Carter et al., 2020; Vanna et al., 2020). The gene discussed is BCL2L1; the disease is acute myeloid leukemia.